RNA-Based Therapeutics Market Overview
The global RNA-Based Therapeutics Market is experiencing steady growth driven by increasing investment in RNA research, rising prevalence of genetic disorders, growing demand for personalized medicine, and advances in RNA delivery technologies. The expanding clinical pipeline for mRNA, RNA interference, antisense oligonucleotides, and other RNA-based modalities is further supporting market development.
According to the Market Research Future report updated August 24, 2026, the global RNA-Based Therapeutics Market was valued at USD 14.65 billion in 2024 and is projected to grow from USD 15.55 billion in 2025 to USD 28.11 billion by 2035, registering a CAGR of 6.1% during the forecast period of 2025–2035. North America dominated the market with a 23.89% revenue share in 2024. mRNA Therapeutics represented the dominant technology, Oncology was the largest application, Pharmaceutical Companies held the largest end-use share, and Liposomes represented the leading delivery method.
Unlock Exclusive Insights – Request Your Free Sample Report Now!
Key players driving innovation and competitiveness in the RNA-Based Therapeutics Market include:
Moderna
BioNTech
Alnylam Pharmaceuticals
Ionis Pharmaceuticals
CureVac
Arcturus Therapeutics
Translate Bio
Sarepta Therapeutics
Dicerna Pharmaceuticals
The RNA-Based Therapeutics Market is being shaped by advances in RNA synthesis, delivery systems, gene silencing, gene editing, and personalized medicine. Lipid-based delivery technologies and other advanced delivery mechanisms are improving the ability to transport RNA molecules to target cells, while increased public and private funding is accelerating clinical development. Regulatory frameworks are also evolving to accommodate the unique characteristics of RNA-based therapies.
The RNA-Based Therapeutics Market can be segmented by Technology, Application, End Use, and Delivery Method. By technology, the market includes RNA Interference, Antisense Oligonucleotides, mRNA Therapeutics, and CRISPR Technology. Applications include Oncology, Infectious Diseases, Genetic Disorders, and Cardiovascular Diseases. End users comprise Pharmaceutical Companies, Research Institutions, and Contract Research Organizations, while delivery methods include Liposomes, Nanoparticles, Viral Vectors, and Electroporation.
The market presents significant opportunities through targeted RNA delivery systems, personalized RNA therapies, expansion into emerging markets, and partnerships between biotechnology companies, pharmaceutical manufacturers, and research institutions. Increasing development of RNA-based solutions for rare and genetic diseases and continued expansion of clinical pipelines are expected to create additional opportunities for market participants.
Recent Developments and Market Trends:
mRNA Therapeutics continues to dominate the technology landscape, supported by its established applications in vaccines and growing potential across therapeutic areas.
RNA Interference is emerging as the fastest-growing technology segment as researchers increasingly explore gene-silencing approaches for genetic disorders and cancer.
Oncology remains the largest application area, while Infectious Diseases are gaining traction through expanding research into RNA-based vaccines and therapies.
Liposomes continue to represent the leading delivery method because of their ability to encapsulate RNA molecules and support cellular uptake, while Viral Vectors are emerging rapidly.
Increasing collaboration between pharmaceutical companies, biotechnology firms, and research institutions is accelerating clinical development and expanding the pipeline of RNA-based therapies.
Reasons to Buy the Report:
Understand the current market size, growth trajectory, and forecast outlook for the global RNA-Based Therapeutics Market through 2035.
Analyze the leading technology, application, end-use, delivery-method, and regional segments shaping market demand.
Evaluate emerging opportunities in mRNA therapies, RNA interference, personalized medicine, genetic disorders, and targeted RNA delivery.
Identify technological developments involving RNA synthesis, delivery systems, gene silencing, and CRISPR-based approaches.
Assess competitive dynamics, investment activity, collaborations, regulatory developments, and strategic opportunities within the RNA-Based Therapeutics Market.
Future Outlook:
The RNA-Based Therapeutics Market is expected to maintain steady growth through 2035 as advances in RNA biology, gene editing, personalized medicine, and delivery technologies continue to expand therapeutic possibilities. mRNA Therapeutics will remain the dominant technology segment, with the segment projected to grow from USD 5.0 billion in 2024 to USD 10.0 billion by 2035, while RNA Interference is identified as the fastest-growing technology. Oncology will remain the leading application, projected to increase from USD 5.0 billion in 2024 to USD 10.0 billion by 2035, while Infectious Diseases will remain an important high-growth opportunity. Pharmaceutical Companies will continue to represent the largest end-user category, accounting for USD 5.86 billion in 2024, while Research Institutions are expected to expand as funding and industry collaboration increase. Liposomes will remain the dominant delivery method, while Viral Vectors are projected to grow from USD 4.5 billion in 2024 to USD 8.0 billion by 2035. North America will retain its leading position, supported by strong biotechnology infrastructure, research funding, and pharmaceutical activity. Overall, the global RNA-Based Therapeutics Market is projected to increase from USD 14.65 billion in 2024 to USD 28.11 billion by 2035 at a CAGR of 6.1%.
➤➤Explore Our Latest Related Reports: